Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lu-177 labeled 6A10-Fab-fragments
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Isotope Technologies Munich
Deal Size : Not Applicable
Deal Type : Not Applicable
ITM and Helmholtz Doses First Patient in Phase I Glioblastoma Investigator-Initiated Trial
Details : ITM-31 is a carbonic anhydrase (CA) XII-specific antibody Fab fragment, which is currently being evaluated for the treatment of glioblastoma.
Brand Name : ITM-31
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 23, 2024
Lead Product(s) : Lu-177 labeled 6A10-Fab-fragments
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Isotope Technologies Munich
Deal Size : Not Applicable
Deal Type : Not Applicable
Medigene Acquires Worldwide, Exclusive License Of CD40L-CD28 Costimulatory Switch Receptor
Details : Under the agreement, Medigene accelerates the expansion of its end-to-end platform of multiple, combinable, exclusive and proprietary technologies with the potential to create best-in-class T cell receptor engineered T cell (TCR-T) therapies for patients...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 02, 2023
Lead Product(s) : ITM-31
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Isotope Technologies Munich
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the license agreement, ITM will hold exclusive rights to the compound ITM-31 as well as the rights to related patents and know-how for the manufacturing and use of ITM-31.
Brand Name : ITM-31
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 19, 2022
Lead Product(s) : ITM-31
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Isotope Technologies Munich
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
